Susser S, Welker MW, Zettler M, Wohnsland A, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C. . Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders tr. J Hepatol . 2008. 48. S29. Find at Google Scholar.
Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, Xia E, Cullen C, Ralston R, Greene J, Tong X. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. . Nucleic Acids Res. . 2009. 37(10). e74. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarraz. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boc. J Viral Hepat. . 2012. 19(2). 120-127. Find at Google Scholar.
Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann . Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected pa. Hepatology. 2009. 50(6). 1709-1718. Find at Google Scholar.
Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L,. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. . Virol J. . 2012. 9. 245. Find at Google Scholar.